Hepatitis-B-Immunglobulin Behring (Human Hepatitis B Immunoglobulin)

Hepatitis‑B‑Immunglobulin Behring is indicated for specific situations where immediate protection against hepatitis B virus is needed.

• Post‑exposure prophylaxis for individuals with recent potential exposure to hepatitis B virus.
• Prevention of hepatitis B infection in newborn infants born to hepatitis B surface antigen‑positive mothers.
• Supplementation of hepatitis B vaccine when rapid immunity is required, such as in immunocompromised patients.
• Use in clinical settings where hepatitis B vaccine response is inadequate or delayed.

The safety profile of Hepatitis‑B‑Immunglobulin Behring reflects the typical reactions observed with intramuscular immunoglobulin preparations.

Common

• Injection‑site pain, redness or swelling.
• Low‑grade fever.
• Headache.
• Fatigue or mild malaise.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face.
• Acute hemolytic transfusion reaction.
• Serum sickness–like illness with rash, fever, joint pain.
• Thromboembolic events such as deep‑vein thrombosis.
• Renal impairment or acute kidney injury.

Before administering Hepatitis‑B‑Immunglobulin Behring, clinicians should consider several precautionary measures.

• Verify patient’s hepatitis B surface antigen and antibody status to avoid unnecessary treatment.
• Assess for known hypersensitivity to human immunoglobulins or any component of the formulation.
• Use caution in patients with a history of severe allergic reactions or anaphylaxis.
• Monitor renal function in individuals with pre‑existing kidney disease.
• Consider the risk of thromboembolic events in patients with cardiovascular disease or prolonged immobility.
• Avoid intravascular administration; ensure proper intramuscular technique.

Hepatitis‑B‑Immunglobulin Behring may interact with other agents, influencing efficacy or safety.

Avoid

• Concurrent administration of live vaccines (e.g., measles‑mumps‑rubella) as passive antibodies can diminish vaccine response.
• High‑dose immunoglobulin products given within 2 weeks, which may increase the risk of hyperviscosity.

Use with caution

• Anticoagulants (e.g., warfarin) because immunoglobulin can affect coagulation parameters.
• Immunosuppressive therapies that may alter the patient’s ability to mount an active immune response.
• Renal‑clearing drugs (e.g., aminoglycosides) in patients with compromised kidney function.
• Blood pressure‑lowering agents, as volume load from the product may affect hemodynamics.